On Nov. 6, Regulus Therapeutics Inc. (NASDAQ:RGLS) announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 10:30 a.m. MST. Regulus Therapeutics Inc. (NASDAQ:RGLS) belongs to Healthcare sector. Its weekly performance is 1.09%. On last trading day company shares ended up $20.47. Regulus Therapeutics Inc. (NASDAQ:RGLS) distance from 50-day simple moving average (SMA50) is 99.19%. Delta Air Lines, Inc. (NYSE:DAL) is launching five new daily round-trip flights from Spokane and Seattle. It’s part of Delta’s ongoing expansion into Seattle and the Pacific Northwest market. Delta Air Lines, Inc. (NYSE:DAL) shares advanced 1.08% in last trading session and ended the day at $43.84. DAL Gross Margin is 46.40% and its return on assets is 18.90%. Delta Air Lines, Inc. (NYSE:DAL) quarterly performance is 17.88%. On Oct 28, Global supercomputer leader Cray Inc. (NASDAQ: CRAY) announced financial results for the third quarter ended September 30, 2014. Revenue for the quarter was $159.4 million, compared to $54.4 million in the third quarter of 2013. The Company reported net income for the quarter of $7.4 million, or $0.18 per diluted share, compared to a net loss of $11.0 million, or $0.29 per diluted share in the prior year period. On 11 November, Cray Inc. (NASDAQ:CRAY) shares fell -0.38% and was closed at $34.47. CRAY EPS growth in last 5 year was 21.50%. Cray Inc. (NASDAQ:CRAY) year to date (YTD) performance is 25.53%. Semiconductor solutions maker Broadcom Corp. (NASDAQ:BRCM) extended its network by adding over 40 channel partners, fortifying its position in the fast-developing Internet of Things (IoT) and high-volume Ethernet IC markets. Broadcom Corp. (NASDAQ:BRCM) ended the last trading day at $41.21. Company weekly volatility is calculated as 1.47% and price to cash ratio as 7.34. Broadcom Corp. (NASDAQ:BRCM) showed a weekly performance of -0.82%. Enzymotec Ltd. (NASDAQ:ENZY) announced the initiation of a clinical study to evaluate the efficacy of Vayarin® in adults with Attention Deficit Hyperactivity Disorder, or ADHD. Enzymotec Ltd. (NASDAQ:ENZY) shares fell -4.51% in last trading session and ended the day at $6.56. ENZY Gross Margin is 57.10% and its return on assets is 7.80%. Enzymotec Ltd. (NASDAQ:ENZY) quarterly performance is -28.07%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
